Assessing the state of Alzheimer’s imaging
Ubicación actual:
>
> This Story

starstarstarstarstar (1)
Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

More Magazine Features

A look back at the remarkable career of Ed Sloan Sr. Celebrating the life and career of the original parts vendor

The value of ISOs in an era of personalization and consolidation The unique value proposition of high quality third-party service

What to look for in an OEM service contract Communication the unique needs of your facility is key to getting the right coverage

The road ahead for breast density awareness It's been a good year for advocacy, here's what happens next

OB/GYN ultrasound: is the field ready to adopt new technology in the market? What do new capabilities mean for creatures of habit?

See All Magazine Features  

Molecular Imaging Homepage

First scan in US performed with uEXPLORER Total-Body PET/CT Can scan an entire patient within 15 to 30 seconds

FDG PET better for measuring Alzheimer's cognitive function than amyloid PET (FDG) PET measures brain glucose consumption

PSMA PET/CT may beat Axumin for locating recurring prostate cancer, says study Researchers at UCLA compare imaging approaches

Progenics collabs with VA on AI research for prostate cancer treatment Apply machine learning to medical images

NNSA awards agreements to US firms for Mo-99 production Will produce with no highly-enriched uranium

ANSTO to hike nuclear medicine prices by as much as nine percent Follows Mo-99 leak

New bill calls for changing reimbursement for radiopharmaceuticals Aims for greater patient access to nuclear medicine exams

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

Assessing the state of Alzheimer’s imaging

por John R. Fischer , Staff Reporter
From the June 2019 issue of DOTmed HealthCare Business News magazine


The use of imaging biomarkers in making an Alzheimer’s diagnosis has led to the shift in the last few years from amyloid-centric to non-amyloid imaging targeting, and introduced new forms of imaging, such as synaptic imaging and neuroinflammation imaging, for assessing. While not specific to Alzheimer’s, neuroinflammation is believed to play a major role in the neurodegeneration process of many neurological conditions, but what that role is, remains unclear.

“We do not know yet if the neuroinflammation is helping or trying to mitigate the disease process, or if the host reaction or neuroinflammation is making neurological diseases worse,” Dr. Satoshi Minoshima, 2018-2019 president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and chairman of radiology and imaging sciences at the University of Utah, told HCB News. “To better understand these questions, we really need to have an in vivo imaging marker,” he said.
Story Continues Below Advertisement

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.




New classes of such drugs have been developed, according to Minoshima, and looking ahead they should provide greater insight on the role of neuroinflammation in Alzheimer’s diagnoses.

Echoing this sentiment is Dr. Jason Cai, an assistant professor from the Yale PET Center at Yale School of Medicine, and part of a team that recently developed a radiotracer for measuring synaptic density, an early and robust biomarker for Alzheimer’s. “I think in the future we will see a combination of amyloid, tau and neurodegeneration PET as biomarkers for AD, hopefully together with structural information from MR imaging.”

Factors currently limiting research
With no treatment or cure in sight for Alzheimer’s, efforts to justify the development of diagnostic agents are sometimes met with skepticism.

“If there is no therapeutic to change the course of the disease, it is hard to justify complex diagnostic tests, especially when they are expensive,” said Minoshima. “With no approved outcome benefit of a therapeutic drug, we cannot change the course of the disease and make a sustainable impact on patients. I think this challenge is going to continue for a while.”

A lack of treatment also means insurers are less inclined to reimburse for diagnostic exams, said Dr. Henryk Barthel, assistant medical director at the department of nuclear medicine at the University of Leipzig, who added that once such a drug becomes available, it’s predicted that the use of molecular imaging in Alzheimer’s will “massively increase” in both clinical routine and research.
<< Pages: 1 - 2 - 3 - 4 >>

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment